Combining immunotherapy and radiotherapy for the STAR treatment

被引:28
作者
Torok, Jordan A. [1 ,2 ]
Salama, Joseph K. [1 ,2 ,3 ]
机构
[1] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC 27708 USA
[2] Duke Canc Inst, Durham, NC 27710 USA
[3] Durham Vet Affairs Med Ctr, Radiat Oncol Serv, Durham, NC 27705 USA
关键词
MULTICENTER; THERAPY; CANCER;
D O I
10.1038/s41571-019-0277-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the past few years, efforts have been made to combine two approaches - immune-checkpoint inhibition and locally ablative radiation therapy - to treat patients with metastatic non-small-cell lung cancer. Herein we discuss the implications of two studies that support the existence of a systemic therapy augmented by radiotherapy (STAR) effect in this setting.
引用
收藏
页码:666 / 667
页数:3
相关论文
共 10 条
  • [1] [Anonymous], 2018, J CLIN ONCOL S
  • [2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [3] Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial
    Bauml, Joshua M.
    Mick, Rosemarie
    Ciunci, Christine
    Aggarwal, Charu
    Davis, Christiana
    Evans, Tracey
    Deshpande, Charuhas
    Miller, Linda
    Patel, Pooja
    Alley, Evan
    Knepley, Christina
    Mutale, Faith
    Cohen, Roger B.
    Langer, Corey J.
    [J]. JAMA ONCOLOGY, 2019, 5 (09) : 1283 - 1290
  • [4] Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
    Gomez, Daniel R.
    Blumenschein, George R., Jr.
    Lee, J. Jack
    Hernandez, Mike
    Ye, Rong
    Camidge, D. Ross
    Doebele, Robert C.
    Skoulidis, Ferdinandos
    Gaspar, Laurie E.
    Gibbons, Don L.
    Karam, Jose A.
    Kavanagh, Brian D.
    Tang, Chad
    Komaki, Ritsuko
    Louie, Alexander V.
    Palma, David A.
    Tsao, Anne S.
    Sepesi, Boris
    William, William N.
    Zhang, Jianjun
    Shi, Qiuling
    Wang, Xin Shelley
    Swisher, Stephen G.
    Heymach, John V.
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1672 - 1682
  • [5] Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
    Luke, Jason J.
    Lemons, Jeffrey M.
    Karrison, Theodore G.
    Pitroda, Sean P.
    Melotek, James M.
    Zha, Yuanyuan
    Al-Hallaq, Hania A.
    Arina, Ainhoa
    Khodarev, Nikolai N.
    Janisch, Linda
    Chang, Paul
    Patel, Jyoti D.
    Fleming, Gini F.
    Moroney, John
    Sharma, Manish R.
    White, Julia R.
    Ratain, Mark J.
    Gajewski, Thomas F.
    Weichselbaum, Ralph R.
    Chmura, Steven J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) : 1611 - +
  • [6] Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
    Ost, Piet
    Reynders, Dries
    Decaestecker, Karel
    Fonteyne, Valerie
    Lumen, Nicolaas
    De Bruycker, Aurelie
    Lambert, Bieke
    Delrue, Louke
    Bultijnck, Renee
    Claeys, Tom
    Goetghebeur, Els
    Villeirs, Geert
    De Man, Kathia
    Ameye, Filip
    Billiet, Ignace
    Joniau, Steven
    Vanhaverbeke, Friedl
    De Meerleer, Gert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05) : 446 - +
  • [7] Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
    Palma, David A.
    Olson, Robert
    Harrow, Stephen
    Gaede, Stewart
    Louie, Alexander V.
    Haasbeek, Cornelis
    Mulroy, Liam
    Lock, Michael
    Rodrigues, George B.
    Yaremko, Brian P.
    Schellenberg, Devin
    Ahmad, Belal
    Griffioen, Gwendolyn
    Senthi, Sashendra
    Swaminath, Anand
    Kopek, Neil
    Liu, Mitchell
    Moore, Karen
    Currie, Suzanne
    Bauman, Glenn S.
    Warner, Andrew
    Senan, Suresh
    [J]. LANCET, 2019, 393 (10185) : 2051 - 2058
  • [8] The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
    Reynders, Kobe
    Illidge, Tim
    Siva, Shankar
    Chang, Joe Y.
    De Ruysscher, Dirk
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (06) : 503 - 510
  • [9] Irradiation and Immunotherapy: From Concept to the Clinic
    Salama, April K. S.
    Postow, Michael A.
    Salama, Joseph K.
    [J]. CANCER, 2016, 122 (11) : 1659 - 1671
  • [10] Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
    Theelen, Willemijn S. M. E.
    Peulen, Heike M. U.
    Lalezari, Ferry
    van der Noort, Vincent
    de Vries, Jeltje F.
    Aerts, Joachim G. J. V.
    Dumoulin, Daphne W.
    Bahce, Idris
    Niemeijer, Anna-Larissa N.
    de Langen, Adrianus J.
    Monkhorst, Kim
    Baas, Paul
    [J]. JAMA ONCOLOGY, 2019, 5 (09) : 1276 - 1282